Stock SHPH SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Delayed Nasdaq
Other stock markets
 12:20:42 2024-06-05 pm EDT 		5-day change 1st Jan Change
0.4896 USD -3.96% Intraday chart for Shuttle Pharmaceuticals Holdings, Inc. -5.85% +7.60%
May. 13 Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 21 Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
AQ
Shuttle Pharma Provides First Quarter 2024 Corporate Update
AQ
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
AQ
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
AQ
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
AQ
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
PR
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
AQ
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
PR
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding
CI
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
PR
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
CI
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
AQ
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
CI
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
PR
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
PR
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program through Exclusive License Agreement
AQ
Shuttle Pharmaceuticals : Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SHPH Stock
  4. News Shuttle Pharmaceuticals Holdings, Inc.